Aptinyx — Technical Presentation (February 2022)
63 slides from Aptinyx's technical presentation, Feb 9, 2022
Slide 1: R&D and Portfolio Review
R&D and Portfolio Review February 9, 2022
Slide 2: Forward-looking statements
2 February 2022 Forward - looking statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 19 95 relating to business, operations, and financial conditions of Aptinyx, including, but not limited to, Aptinyx’s belief in t
Slide 3: Discovering and developing innovative therapies for CNS disorders
February 2022 3 Discovering and developing innovative therapies for disorders of the central nervous system Science - driven, leading NMDA receptor platform Focused on indications of major unmet need Striving to improve the lives of patients
Slide 4: Agenda
Agenda February 2022 Andy Kidd, M.D. President & Chief Executive Officer 4 Company overview NMDA receptor positive allosteric modulation A novel mechanistic approach to treating CNS disorders Harald Murck, M.D., Ph.D. Vice President, Clinical & Medical Affairs Clinician’s perspective Treating painfu
Slide 5: NMDA receptor hypofunction in neurological and neuropsychiatric disorders
February 2022 5 Learning, memory, executive function, and the cognitive control of pain and emotion are directly regulated by NMDAr function in key brain regions NMDA receptor hypofunction in certain brain regions is implicated in a range of neurological and neuropsychiatric disorders Prefrontal Cor
Slide 6: Pipeline primed for late-stage development with five ongoing Phase 2 studies
PROGRAM INDICATION 1Q 2022 2Q 2022 3Q 2022 4Q 2022 1Q 2023 2Q 2023 3Q 2023 4Q 2023 1Q 2024 NYX - 2925 Painful DPN Fibromyalgia NYX - 783 NYX - 458 Cognitive Impairment in PD & DLB Phase 2b Readout Pipeline primed for late - stage development with five ongoing Phase 2 studies across indications of hi
Slide 7: Patient populations by indication
PTSD Cognitive Impairment Parkinson’s Disease & DLB Painful DPN ~1.4M people (U.S.) Frontiers in Neuroscience (2021) | National Fibromyalgia Association | Amer. College of Rheumatology | U.S. Dept. of Veteran’s Affairs: National Center for PTSD | Lewy Body Dementia Association ~8.5M people (U.S.) ~1
Slide 8: Painful DPN and fibromyalgia represent blockbuster commercial opportunities
February 2022 8 Novel treatments for painful DPN and fibromyalgia each represent blockbuster commercial opportunities due to volume and unmet need $7.5B+ Combined U.S. peak annual sales for pregabalin (Lyrica) and duloxetine (Cymbalta) prior to genericization 50M+ U.S. patient population across pain
Slide 9: High rate of discontinuation among first line therapies in painful DPN
… 74% 61% 50% 36% 67% 53% 39% 28% 64% 51% 36% 23% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 30 days 90 days 180 days 365 days Duloxetine Gabapentin Pregabalin High rate of discontinuation among first line therapies in patients being treated for painful DPN discontinue treatment after 1 year ~ 70 %
Slide 10: Abuse potential of commonly used therapies is a critical issue
February 2022 10 The abuse potential associated with commonly used therapies is a critical issue in pain management and will differentiate future therapies Long considered safe and non - addictive, gabapentin is increasingly showing up in the bodies of people who overdose on heroin and prescription
Slide 11: NMDA receptor positive allosteric modulation
February 2022 11 NMDA receptor positive allosteric modulation Novel discovery platform and approach to treating disorders of the central nervous system
Slide 12: Aptinyx compounds target NMDAr hypofunction
February 2022 Unlike other NMDAr mechanisms, Aptinyx compounds are designed to target NMDAr hypofunction to retore normal CNS activity 12 ANTAGONIST AGONISTS Excitotoxicity (Broad - based activity) Normal Balance (Targeted activity) Disassociation & Abuse Risk (Broad - based activity) APTINYX PAM Gl
Slide 13: Activation of NMDA receptors balances calcium influx and enhances synaptic plasticity
13 Activation of NMDA receptors results in balance to calcium influx and enhances synaptic plasticity NYX H ypoactivity Increased neural firing February 2022 1 2 4 3 NMDAr hypofunction from glutamatergic dysregulation NYX binds to NMDAr and facilitates Ca ++ influx Ca ++ influx leads to new NMDAr an
Slide 14: Centralization of pain processing in key brain regions
February 2022 14 Centralization of pain processing in key brain regions is evident in patients with fibromyalgia and painful DPN Over time, the processing of peripheral pain shifts from… Sensory brain regions Time Centralized Processing (Chronic Pain ) Peripheral Processing (Acute Pain) Emotional, l
Slide 15: NYX-2925 targets aberrant centralized pain processing in the PFC
NYX - 2925 targets aberrant centralized pain processing resulting from NMDA receptor hypofunction in the PFC 15 February 2022 The prefrontal cortex (PFC) plays a critical role in regulating the e motional and cognitive aspects of centralized pain processing C entralized pain can arise from altered b
Slide 16: NYX-2925 favorable safety, tolerability, and PK profile
February 2022 16 NYX - 2925 has demonstrated a favorable safety, tolerability, and PK profile, representing a significant potential differentiator Rationally designed to bind to the NMDA receptor Targeted activity at hypofunctioning receptor / regions No off - target effects shown in 80 - receptor C
Slide 17: NYX-2925 NMDA PAM to treat chronic pain
February 2022 17 NYX - 2925 NMDA positive allosteric modulator to treat chronic pain
Slide 18: Phase 2a studies of NYX-2925 in painful DPN and fibromyalgia
February 2022 18 Phase 2a studies of NYX - 2925 in painful DPN and fibromyalgia have informed Phase 2b studies Phase 2a – Painful DPN Large Phase 2b studies are underway across painful DPN and fibromyalgia to further characterize therapeutic profile and validate early signals Phase 2a – Fibromyalgia
Slide 19: Concomitant medications cloud efficacy in Phase 2a DPN study
Key learning from exploratory Phase 2a DPN study: Concomitant medications cloud efficacy and are unnecessary for enrollment Efficacy Population Not on Concomitant Analgesic (n=148) Total Efficacy Population (n=300) CHANGE IN AVERAGE DAILY PAIN (PRIMARY EFFICACY ENDPOINT) 25% reduction in pain 0.58 -
Slide 20: Change in average daily pain by DPN duration
- 1.62 - 1.51 - 1.77 - 1.93 - 2.12 - 1.26 - 1.26 - 1.04 - 0.72 - 0.93 -2.5 -2 -1.5 -1 -0.5 0 ≥ 1 yrs (n=275) ≥ 2 yrs (n=204) ≥ 3 yrs (n=151) ≥ 4 yrs (n=127) ≥ 5 yrs (n=95) Change in NRS (0 - 10) Pain Score from Baseline 50mg Placebo Change in Average Daily Pain (Baseline to Week 4) by DPN Duration n
Slide 21: Significant effects in advanced DPN subset inform Phase 2b design
35% reduction in pain 1.8 - point separation from placebo Significant effects observed in a large subset of patients in Phase 2 painful DPN study inform Phase 2b design CHANGE IN AVERAGE DAILY PAIN (PRIMARY EFFICACY ENDPOINT) Advanced DPN Pop. Not on Concomitant Analgesic ( n= 64)* *Retrospective an
Slide 22: Design of Phase 2b study of NYX-2925 in painful DPN
DESIGN OF PHASE 2b STUDY OF NYX - 2925 IN PAINFUL DPN 12 - week treatment period Advanced DPN population (4+ years) No concomitant analgesics Primary endpoint: Change in average daily pain on the Numerical Rating Scale (NRS) Other endpoints: Worst daily pain, daily sleep interference, pain on walkin
Slide 23: NYX-2925 modifies pain-induced brain activity in key brain regions
23 NYX - 2925 MODIFIES PAIN - INDUCED BRAIN ACTIVITY IN KEY BRAIN REGIONS NYX - 2925 produced statistically significant reductions of glutamate and glutamine in key pain - regulating brain regions vs. PBO Also observed reduced functional connectivity with NYX - 2925 in certain brain regions vs. PBO
Slide 24: NYX-2925 improvements in patient-reported measures of fibromyalgia
0.2 - 3.2 - 5.4 0.4 -8.0 -7.0 -6.0 -5.0 -4.0 -3.0 -2.0 -1.0 0.0 1.0 PBO (Wk 2) 20mg (Wk 4) 200mg (Wk 6) Follow-Up Mean Change from Baseline - 2.9 - 3.8 - 9.6 - 0.4 -14.0 -12.0 -10.0 -8.0 -6.0 -4.0 -2.0 0.0 PBO (Wk 2) 20mg (Wk 4) 200mg (Wk 6) Follow-Up Mean Change from Baseline - 0.3 - 0.4 - 1.0 - 0.
Slide 25: Design of Phase 2b study of NYX-2925 in fibromyalgia
DESIGN OF PHASE 2b STUDY OF NYX - 2925 IN FIBROMYALGIA 12 - week treatment period No concomitant analgesics Primary endpoint: Change in average daily pain on the Numerical Rating Scale (NRS) Other endpoints: Worst daily pain, daily sleep interference, FIQR, PROMIS Key learnings from previous Phase 2
Slide 26: Clinician's perspective: Treating painful DPN and fibromyalgia
February 2022 26 Clinician’s perspective Treating painful DPN and fibromyalgia Richard Rauck, M.D. B oard - certified physician in pain medicine , Carolinas Pain Institute Medical Director and CEO, Center for Clinical Research
Slide 27: A Clinician's Perspective: Treating Painful DPN and Fibromyalgia
A Clinician’s Perspective: Treating Painful DPN and Fibromyalgia Richard L. Rauck MD President, Carolinas Pain Institute Past President, World Institute of Pain Medical Director and CEO, Center for Clinical Research
Slide 28: Objectives of Talk
Objectives of Talk • Review painful DPN and fibromyalgia • Discuss the currently available treatment options • Describe how current therapies are failing to address the needs of patients • Present the need for an effective, safe, novel, non - opioid pharmacologic treatment in painful DPN and fibromy
Slide 29: Painful DPN and Fibromyalgia Disease Overview
Painful DPN and Fibromyalgia Disease Overview • Prevalence: 8.5 million in PDPN ( Frontiers in Neuroscience ) and approximately 8+ million in fibromyalgia (American College of Rheumatology and National Fibromyalgia Association) • Painful DPN starts as a peripheral pain problem that is believed to ce
Slide 30: Pain: +- +44
Pain: +- +44 ‘Tendon reflex: N= Tendon reflex: Tendon reflex: N Motor deft: 0 nebi.nim.nih.gov
Slide 31: Fibromyalgia
Fibromyalgia • American College of Rheumatology: • 11 of 18 tender areas positive • Pain above and below umbilicus • Pathophysiology is poorly understood • No peripheral abnormalities • Significant co - morbid psychological and physiologic disturbances • Fibromyalgia is a centralized pain syndrome
Slide 32: Centralization of Chronic Pain
Centralization of Chronic Pain Remember: All pain is perceived in the brain
Slide 33: Patient Profile: Painful Diabetic Neuropathy
Patient Profile: Painful Diabetic Neuropathy • 58 year old male, 236 lbs, 5’9”; BMI 35 (morbidly obese) • Type II DM for 12 years: increasing stocking glove paresthesias in feet extending to mid calf with tingling in both hands past 24 months • Pain in the lower extremities often described as anesth
Slide 34: Patient Profile: Painful Diabetic Neuropathy (continued)
Patient Profile: Painful Diabetic Neuropathy • Patient initially managed by his PCP: PCP trialed pregabalin, gabapentin and duloxetine. PCP continues to manage Hgb AIC • Hgb AIC ranges from 7 - 8.5 • PCP referred to pain clinic when patient wanted to try opioids • I trialed 3 different opioids and r
Slide 35: Patient Profile: Fibromyalgia
Patient Profile: Fibromyalgia • 38 year old female, BMI 26, married, 2 children • Diffuse widespread pain with 15/18 positive tender areas • VAS: 7 - 8/10 on good days; 9 - 10/10 on bad days. Reports 4 - 5 bad days/week. • On bad days, she is either in bed or on the couch for majority of day • Pain
Slide 36: Use of Gabapentin in Chronic Pain Conditions
Use of Gabapentin in Chronic Pain Conditions • Many studies in many different pain states • Gabapentin is used clinically in many of the conditions where it has not shown utility in clinical trials (LBP and CRPS) • Effect size is small in many of these trials • Number of participants is limited in m
Slide 37: Practice Guideline Update Summary for Painful Diabetic Polyneuropathy
Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary • Gabapentinoids: SMD 1 = 0.44 (95% confidence interval [CI]: 0.25 - 0.63) – small - to - medium effect, are “probably” more likely than placebo to improve pain • Gabapentin: SMD = 0.53 (95% CI: 0.22 - 0
Slide 38: Cochrane Reviews for Pharmacologic Efficacy in Painful DPN and Fibromyalgia
Cochrane Reviews for Pharmacologic Efficacy in Painful DPN and Fibromyalgia • Numbers needed to treat (NNT) for gabapentin in painful DPN was 5.9 in 1277 patients • NNT for moderate relief (30%) was 6.6 in 1439 DPN patients • NNT for antiepileptics in fibromyalgia was between 4 - 10 • 50% pain reduc
Slide 39: FDA requires new warnings for gabapentinoids
FDA In Brief: FDA requires new warnings for gabapentinoids about risk of respiratory depression December 19, 2019 ‘The following quote is attributed to Douglas Throckmorton, M.D., deputy director for Regulatory Programs in the FDA's Center for Drug Evaluation and Research: “With the evolution of the
Slide 40: Opioid Prescribing Patterns in US
Opioid Prescribing Patterns in US Health Care Cost Institute, 2019
Slide 41: Three Waves of the Rise in Opioid Overdose Deaths
Three Waves of the Rise in Opioid Overdose Deaths > Any Opioid 15 w Opl £3 Bn Other Synthetic Opioids Bou (4. TamadolorFentanyt & to sees or ey manure) 8 8 87 = 6 a os Heroin 33 ‘Commonly Prescribed Opioids g: ina sense on 1 ° 2019 Wave 1: Rise in Prescription Opioid ‘Overdose Deaths ‘Started in 199
Slide 42: National Overdose Deaths Involving Any Opioid
Figure 3. National Overdose Deaths Involving Any Opioid, Number Among All Ages, by Gender, 1999-2020 100,000 Total — Female 80,000 — Male 68,630 60,000 47,600 40,000 21,089 20,000 ° REgRREREREE 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Among deaths with drug overdose as the underlying c
Slide 43: Unmet Need for a New, Novel, Non-opioid Medication for Chronic Pain
Unmet Need for a New, Novel, Non - opioid Medication for Treatment of Chronic Pain • Opioid epidemic is driving an intense search for better alternatives to treat and manage chronic pain of all types • To date, failure of many novel drugs (e.g. anti - nerve growth factor class) • NIH HEAL (The Helpi
Slide 44: Desired Profile of a Safe and Effective Treatment Option for Chronic Pain
The Desired Profile of a Safe and Effective Treatment Option for Chronic Pain in General • Statistically significant separation from placebo in clinical trials – an FDA requirement for approval • Clinically meaningful efficacy (% improvement in pain, response rates, and efficacy trade - off in the c
Slide 45: Clinically Significant Results versus Statistical Significance
Considerations of Clinically Significant Results versus Statistical Significance • In my opinion clinical significance (or meaningfulness) cannot be ascertained from any clinical trial • Too many confounding problems in a clinical trial setting • FDA (analgesic division) has implied that statistical
Slide 46: Novel Molecules for Chronic Pain Enhanced with Central Effect
Therapeutic Benefit of Novel Molecules for Chronic Pain Are Greatly Enhanced with Central Effect • There are clearly peripheral pain generators but the pathophysiology in the periphery with chronic pain is not often clear • Examples: • Chronic low back pain (EU project on genetics and LBP) • Painful
Slide 47: Peripherally versus Centrally Acting Analgesics
Peripherally Acting versus Centrally Acting Analgesics for the Management of Chronic Pain • Peripherally acting analgesics: • Acetaminophen • paracetamol • Aspirin • NSAIDs • Steroids • Anti - nerve growth factor monoclonal antibodies • Nav 1.7 and 1.8 inhibitors • Centrally acting analgesics: • Opi
Slide 48: Disruption to Excitatory and Inhibitory Function in Medial Prefrontal Cortex
Disruption to Normal Excitatory and Inhibitory Function within the Medial Prefrontal Cortex in People with Chronic Pain • Comparison of medial prefrontal neurochemistry in 24 persons with chronic pain to 24 age and sex - matched controls without pain • GABA and glutamate levels measured week before,
Slide 49: Pain
PAIN Sensitization of the nociceptive fibers cause pain perception from non-painful sensory stimuli Descending fibers inhibition Dorsal horn of the spinal cord Ascending fibers Dorsal ganglia of the spinal roots Spina cord Peripheral ‘ — Peripheral nerve nociceptors
Slide 50: Conclusions
Conclusions • Painful DPN and fibromyalgia continue to grow in prevalence and remain large unmet needs in the chronic pain community • Opioids are ineffective and often harmful and will continue to decline in use • Pharmacotherapy effectiveness is limited and often with significant side effects • Th
Slide 51: NYX-783 NMDA PAM to treat PTSD
February 2022 51 NYX - 783 NMDA positive allosteric modulator to treat PTSD
Slide 52: Targeting NMDA receptor hypofunction supports development in PTSD
February 2022 52 Targeting NMDA receptor hypofunction in key brain regions supports therapeutic development in PTSD HYPOACTIVE REGIONS REGULATE FEAR EXTINCTION LEARNING AND COGNITIVE CONTROL OF EMOTION GLUTAMATERGIC DYSREGULATION AND PFC HYPOFUNCTION Hypoactive regions Hyperactive regions Activation
Slide 53: NYX-783 Phase 2a clinically meaningful improvement of PTSD symptoms
- 35% - 29% - 43% Stage 1 - Week 4 p=0.105 vs placebo MMRM LSM % Change from Baseline WEEK 4 CAPS - 5 (Clinician Administered PTSD Scale – DSM 5 th Edition) | All statistical analyses represent 1 - sided analysis 53 CAPS - 5 TOTAL SCORE – “Clinically Reliable Change” CAPS - 5 TOTAL SCORE WEEK 4 In e
Slide 54: Design of Phase 2b PTSD program
D esign of Phase 2b PTSD program incorporates key learnings from Phase 2 exploratory study 10 - WEEK TREATMENT PERIOD ~300 patients – civilian and military PTSD 10 weeks of daily treatment Randomized, parallel, double - blind design No concomitant PTSD pharmacotherapies (SSRIs) Primary endpoint: Cha
Slide 55: NYX-458 NMDA PAM to treat cognitive impairment in PD and DLB
February 2022 55 NYX - 458 NMDA positive allosteric modulator to treat c ognitive impairment associated with Parkinson’s Disease and D ementia with Lewy Bodies
Slide 56: Targeting NMDA receptor hypofunction in cognitive impairment in PD and DLB
February 2022 56 Targeting NMDA receptor hypofunction supports therapeutic development in cognitive impairment in PD and Dementia with Lewy Bodies Hypoactive regions Hyperactive regions HYPOACTIVE REGIONS IN PARKINSON'S DISEASE REGULATE EXECUTIVE FUNCTION, WORKING MEMORY, AND ATTENTION GLUTAMATERGIC
Slide 57: Alpha-synuclein increase results in decreased NMDA receptor activity
Alpha - synuclein increase in Parkinson’s disease and dementia with Lewy bodies results in decreased NMDA receptor activity CLEAR MECHANISTIC RATIONALE Parkinson’s disease and dementia with Lewy bodies share a common disease pathology α - synuclein build - up has been implicated as a causal factor f
Slide 58: NYX-458 reverses cognitive impairment in preclinical models
NYX - 458 reverses cognitive impairment in preclinical models, including translatable non - human primate model of Parkinson’s disease Improvements observed with NYX - 458 across attention, working memory, and executive function After re - induced impairment, replication of NYX - 458 effects observe
Slide 59: Exploratory Phase 2 study of NYX-458 in PD and DLB cognitive impairment
Exploratory Phase 2 study of NYX - 458 in cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies Data from exploratory Phase 2 study expected 4Q 2022 / 1Q 2023 Placebo QD 12 - WEEK TREATMENT PERIOD SCREENING & BASELINE (UP TO 4 WEEKS) N=100 STUDY ELIGIBILITY EVALUATIO
Slide 60: Closing thoughts
February 2022 60 Closing thoughts
Slide 61: NYX-2925 novel mechanistic approach to major unmet needs in chronic pain
NYX - 2925 represents a novel mechanistic approach to address the major unmet needs in treating chronic pain Potential for abuse liability with current therapies (opioids, gabapentinoids) High rate of treatment discontinuations stemming from harmful side effects Ineffective treatments for chronic pa
Slide 62: Strong balance sheet funds Phase data catalysts into 2023
62 February 2022 Strong balance sheet funds Phase 2 data catalysts across all pipeline programs and operations into 2023 Cash and equivalents (unaudited) (December 31, 2021) $106M Remaining capital credit facility (K 2 HealthVentures) $ 35 M
Slide 63: Q&A session
February 2022 63 Q&A session